Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05764239 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
A Phase 3 study, sponsored by Synlogic.
- Terminated
- Registry status
- Phase 3
- Development phase
- 35
- Enrollment target
NCT05764239 is a Phase 3 study that was terminated before completion, run by Synlogic. The registered enrollment target is 35 participants.
The verdict
NCT05764239, a Phase 3 study, was terminated before completion, sponsored by Synlogic.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 35 participants
- Enrollment target
Study Summary
SYNB1934-CP-003 was designed as a 3-part, adaptive study consisting of a dose-escalating, open-label period (DEP; Part 1) of up to 15 weeks, followed by a 4-week, double-blind, placebo-controlled, randomized withdrawal period (RWP; Part 2), and an open-label extension (OLE; Part 3) of up to 36 months
Interventions
- DRUG Placebo
- DRUG SYNB1934v1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-07-05 |
| Est. Completion | 2024-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05764239
The ClinicalTrials.gov registry entry for NCT05764239 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synlogic, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05764239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05764239 about?
NCT05764239 is a clinical study titled "Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)". SYNB1934-CP-003 was designed as a 3-part, adaptive study consisting of a dose-escalating, open-label period (DEP; Part 1) of up to 15 weeks, followed by a 4-week, double-blind, placebo-controlled, randomized withdrawal period (RWP; Part 2), and an open-label extension (OLE; Part 3) of up to 36 month...
What is the current status of trial NCT05764239?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 35 participants. The study started on 2023-07-05. Estimated completion is 2024-03-15.
What interventions are being tested in trial NCT05764239?
The interventions under investigation include: Placebo (DRUG), SYNB1934v1 (DRUG).
Who is sponsoring clinical trial NCT05764239?
This trial is sponsored by Synlogic, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.